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Abstract
Plasma exchange (PEX) is a treatment method with increasing range of indications. 
However, due to the small number of randomized trials, its effectiveness is still under 
debate in certain conditions. The aim of our chapter is to present the major principles 
of PEX, discuss safety issues and reveal current data for treatment effectiveness of the 
method. Novel indications for PEX will also be discussed.
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1. Introduction
Plasma exchange (PEX) is an invasive therapeutic method, separating plasma from blood cells. 
Thus, pathogenic antibodies or other large molecules are removed and plasma is replaced by 
human albumin and/or fresh frozen plasma (FFP). The method was first developed in the first 
half of the twentieth century. Over the years a significant improvement in the PEX technique, 
patient safety and broadening of indications were observed. Selective techniques were also 
introduced into practice, leading to selective removal of proteins and reduction of protein 
loss during the standard procedure, especially fibrinogen. Thus, improved effectiveness and 
patient safety was achieved.
2. Plasma exchange: basic principles
Generally, in PEX, blood is pumped out of the patient’s circulation and is transferred to the fil-
ter, separating plasma from blood cells. Afterwards, blood cells are pumped into the patient’s 
vein. Patient’s plasma is substituted by human albumin and/or FFP.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2.1. Vascular access
In most of the cases, central venous catheters are used in PEX, especially in acute conditions. 
They can be placed in internal jugular, femoral and subclavian veins. However, if life-long treat-
ment is needed (e.g., LDL apheresis), arteriovenous fistula creation may be required. In addi-
tion, as the blood flow is low (90–150 ml/min), large peripheral veins can be used (cubital veins). 
Single-vein access is also possible but in cases where centrifugal separation of plasma is used.
2.2. Separation techniques
Plasma is separated from blood cells via two major methods—centrifugal and hollow-fiber 
membrane separator. In addition, more selective methods were developed.
2.2.1. Centrifugal separation
The separator is a disposable rotating centrifugal bowl. Blood runs into the bowl and cen-
trifugal force separates blood cells from plasma. Blood cells are pumped back into patient’s 
circulation, whereas plasma is separated in sterile bags. The process can occur simultaneously 
or intermittently. There is no upper limit for the size of the molecules removed by centrifugal 
PEX. Usually the blood flow ranges between 90 and 150 ml/min. A major disadvantage of 
centrifugal PEX is platelet count reduction, which may reach up to 50% [1].
2.2.2. Membrane PEX
In this type of PEX, highly permeable hollow fiber membrane filters are used. The fibers have 
pores with diameter ranging from 0.2 to 0.5 μm. As blood runs through the fibers plasma is 
separated from the blood cells, which are returned in patient’s circulation. All immunoglobu-
lins are effectively cleared by this method. However, its effectiveness is poorer in immune 
complexes and cryoglobulins. The risk for platelet count reduction is small. Yet, there is a 
risk for hemolysis, especially if faster blood flow is used (normal values for the method are 
90–200 ml/min). Synthetic membranes are used; plasma filters should not be reused [1].
2.2.3. Selective separation techniques
The abovementioned plasma separation techniques remove plasma from whole blood, thus 
causing loss of normal proteins, especially coagulation factors and albumin. In order to reduce 
protein loss, selective PEX techniques were introduced into practice.
2.2.3.1. Double cascade PEX
Cascade filtration is a semi-selective separation technique, in which after initial separation of 
plasma from blood cells, additional filtration of plasma is performed with different diameters 
of fiber pores, so that target protein fractions are filtered and the rest are pumped back in cir-
culation. This technique showed up to 70% reduction in albumin loss after the procedure [2].
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2.2.3.2. Cryofiltration
The method is used to remove cryoglobulins in several immune diseases. After plasma is ini-
tially filtrated, it is cooled to 4°C. This causes precipitation of cryoglobulins and they do not 
pass the second membrane. Afterwards, the cooled plasma is warmed to body temperature 
again and is returned to the patient.
2.2.3.3. Thermofiltration
Similar to cryofiltration, plasma is firstly separated from whole blood. Before the selective 
filtration, the filtrate is warmed up to 40°C, causing aggregation of VLDL and LDL molecules. 
Then second filtration is performed and the filtrate is introduced back into patient’s blood. 
The method is not widely used due to the fact that little is known about the changes in large 
molecules after being exposed to higher temperatures [2].
2.2.3.4. Unselective adsorption
Unselective adsorption uses charcoal or ion exchange raisins to remove exogenous or endo-
genic toxins from blood (hemoperfusion) or from filtered plasma (plasmaperfusion). These 
methods are most commonly indicated in exogenous intoxications. There are reports that 
hemoperfusion was effective in sepsis, septic shock and disseminated intravascular coagu-
lopathy [3]. Currently, plasmaperfusion is gaining ground over hemoperfusion due to its 
improved effectiveness and improved safety profile.
2.2.3.5. Selective adsorption
In selective adsorption the initial filtrate runs through prearranged immunosorbents. Thus, 
specific antibodies can be selectively removed, whereas albumin and clotting factors are 
returned to the patient. There are two types of selective adsorption—immunoadsorbtion (IA) 
and selective plasma adsorption. In IA, either the plasma runs through column bearing antigens 
directed against certain antibodies or antibodies against certain plasma constituents. In selec-
tive plasma adsorption, plasma components are removed by binding to ligands other than 
antibodies and antigens (e.g. heparin and dextransulfate in LDL adsorption).
Different immunoadsorbtion (IA) techniques exist, but protein A-based IA is the most com-
monly used one. Protein A is a Staphylococcus aureus-derived molecule that binds to the 
Fc-region of immunoglobulin G (IgG). The principle of the procedure is similar to the pre-
vious selective methods—plasma is firstly separated from blood and then the filtrate runs 
through protein A—containing filters. Thus, immunoglobulins (IgG) and immune com-
plexes are removed and the filtrate is pumped back into circulation. The method is well 
tolerated and is used in the following situations: acute antibody-mediated rejection, pre-
sensitized kidney transplant (KT) candidates, systemic lupus erythematosus (SLE), Guillain-
Barrè syndrome, Goodpasture syndrome, myasthenia gravis, hemolytic uremic syndrome 
(HUS) and so on.
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Other adsorbents can carry antibodies against proteins to be removed too. Polyvinyl-alcohol 
gel, bound to tryptophan, is used for removal of anti-acetylcholine-receptor antibodies in 
myasthenia gravis; phenylalanine-bound polyvinyl-alcohol gel for selective removal of anti-
DNA antibodies; and cardiolipin antibodies in SLE [2].
2.3. Anticoagulation
Practically in all PEX procedures, anticoagulation is needed. In centrifugal PEX, usually 
citrate anticoagulation is used, whereas in membrane PEX, heparin is the anticoagulant of 
choice [1]. Citrate has advantages in patients with high bleeding risk, as it has no influence 
on systemic coagulation, but it is associated with increased incidence of hypocalcaemia. The 
usual dose of heparin is bolus dose 2000–5000 IU, followed by infusion of 500–2000 IU per 
hour. Anticoagulants are administered pre-filter. Low-molecular weight heparins (LMWH) 
can be used too. They are associated with lower incidence of side effects and more selective 
prevention of clotting. In our institution low-molecular weight heparins are used in doses, 
0.01 ml/kg body weight or generally 0.8–1.0 ml LMWH per procedure.
2.4. Substitution fluids
PEX requires large volumes of replacement fluids. A single procedure was found to reduce 
plasma macromolecule levels by 60% [4]. The use of crystalloids is ineffective, as they are 
not capable of preserving the intravascular oncotic pressure. Gelatin-based plasma expanders 
have limited practical importance, as they have shorter half life compared to albumin-based 
fluids. Therefore, the most widely used substitution fluid is human albumin. Replacement 
volume reaches 50 ml/kg, 4–5% human albumin per procedure. The major disadvantage of 
albumin replacement is the lack of coagulation factors. Therefore fresh frozen plasma (FFP) 
can be applied after PEX. In certain diseases, the replacement fluid should consist of FFP 
only— for example, HUS, thrombotic thrombocytopenia purpura (TTP) and so on. Other 
indications for FFP use are reduction of plasma fibrinogen level below 1.25 g/l, increase of 
prothrombin time more than 2 s above normal values and increased risk of bleeding (pulmo-
nary hemorrhage, 48 h after biopsy/surgery) [1]. FFP should be used with caution, as its appli-
cation is associated with hypotension, citrate-associated paraesthesia, urticaria, anaphylaxis 
and blood-borne infections.
2.5. Treatment volume: frequency of PEX
2.5.1. Treatment volume
A formula for determining the needed volume of single PEX was suggested by A.A. Kaplan [5]:
  Volume PEX =  [0.065 ∗ body weight (kg) ] ∗  (1 − Hct) (1)
where kg: kilograms and Hct: hematocrit.
Plasma Medicine - Concepts and Clinical Applications62
An easier way to assess the needed PEX volume is 30–50 ml/kg body weight.
2.5.2. Frequency of PEX
PEX is usually performed daily or every other day. The duration of treatment is 10–14 proce-
dures, but it can be guided by clinical outcomes and laboratory results (auto-antibody titers, 
platelet count, etc).
2.6. PEX: mechanism of action
PEX and IA have beneficial effects on different diseases due to the following mechanisms [2]:
• Elimination of pathological constituents—alloantibodies/autoantibodies, paraproteins, 
 circulating immune complexes, toxins and so on.
• Substitution of plasma proteins: clotting factors, hormone carrier proteins, immunoglobu-
lins and so on.
• Modifying immune cells’ functions: deblocking of reticuloendothelial system and modify-
ing lymphocyte response.
2.6.1. Immunosuppressive treatment in PEX
Despite the mentioned beneficial effects, PEX is not effective in immune disease when used 
alone, as it influences pre-existing pathological molecules and has no influence on their for-
mation. It was established that the procedure causes rapid decrease in antibody titers, which 
is followed by increased antibody production and B-cell proliferation [6]. In addition, the 
combination PEX and immunosuppressive therapy has better results compared to using 
plasma exchange and immunosuppression alone.
Several combinations have been suggested. Initially, steroids of 1–2 mg/kg for 2–3 weeks or 
cyclophosphamide of 2–3 mg/kg for 2–3 weeks, followed by azathioprine of 1–2 mg/kg for 
several months after cyclophosphamide treatment, were suggested. Later, cyclophosphamide 
pulses and PEX were found superior to oral intake and PEX [7]. Over the last years new 
immunosuppressive agents have been introduced as concomitant therapy in PEX—cyclospo-
rine A, tacrolimus and mycophenolic acid [8]. In addition, biological agents are more widely 
used—monoclonal antibodies (e.g., rituximab) and intravenous immunoglobulin (IVIG). 
Rituximab is usually applied, 375 mg/m2/weekly, for 2–4 weeks. IVIG is applied, 100 mg/kg, 
after each PEX [9, 10].
2.6.2. Additional medications
Calcium gluconate and potassium chloride can be infused to counterbalance PEX-associated 
hypocalcaemia and hypokalemia.
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3. Contraindications to plasma exchange: complications
3.1. Contraindications to PEX
The major contraindications to PEX are hemodynamically unstable patients, sepsis, history 
for allergy to human albumin or FFP.
3.2. Complications
Generally, the procedure is safe, and though the incidence of all complications peaks to 40%, 
the risk for life-threatening adverse events (defined as death, hypotension-requiring vaso-
pressor agent, arrhythmias, medical intervention and hemolysis) is low, ranging between 
0.025 and 4.75% [11, 12]. There are three groups of complications in PEX, which are summa-
rized in Table 1.
As the most serious complication, death has incidence of up to 0.05%, though most of the 
patients were with severe pre-existing conditions [2]. However, the complication rate var-
ies across registries, as mortality was 0% in the Swedish apheresis data base, encompass-
ing more than 20,000 procedures. Yet the same trend was observed—overall complications’ 
rate reached 4.3%, of which just 0.9% were serious adverse events [13].The highest risk for 
complications was detected in unstable patients, hypotension, active bleeding, bronchial 
Vascular access-associated Hematoma
Infection/sepsis
Pneumothorax
Substitution 
therapy-associated
Anaphylaxis to FFP
Death, due to anaphylaxis
Coagulopathy
Blood-borne infections
Hypocalcaemia
Hypokalemia
Other Hypotension
Dyspnea
Low platelet count
Hemolysis
Drug and vitamin removal
Death, due to cardiac arrest, pulmonary edema and pulmonary embolism
Anaphylactoid reactions, hypotension, flushing due to ACE inhibitors and the use of 
dextran sulfate systems for LDL apheresis
FFP: fresh frozen plasma, ACE inhibitors: angiotensin-converting enzyme inhibitors, LDL: low-density lipoprotein.
Table 1. Complications in plasma exchange.
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obstruction and anemia [14]. In addition, the complications are significantly more in PEX with 
FFP substitution, compared to human albumin only.
Similar results were observed in our institution. In 51 PEX procedures no life-threatening 
complications were detected. Two episodes of hypotension were established, not requiring 
vasopressor agents. Two patients developed paraesthesia. Laboratory results prior and after 
PEX remained stable (hemoglobin level, white blood cell count, platelet count and potassium 
and calcium levels). An expected drop in fibrinogen, immunoglobulin A and G levels, was 
detected, without bleeding or infection episodes, associated with the procedure [15].
In conclusion, though the procedure is relatively safe, due to the risk for serious complica-
tions, it should be performed by experienced personnel.
3.3. Indicators to monitor during PEX treatment
3.3.1. Clinical indicators
The basic clinical parameters should be monitored prior to and after the procedure—blood 
pressure, heart rate and body temperature. Clinical assessment can be performed at shorter 
intervals of time during the procedure in unstable patients.
3.3.2. Laboratory indicators
Full blood count, plasma calcium, plasma potassium, fibrinogen levels and prothrombin time 
should be evaluated after each procedure. Other laboratory tests can be performed prior to 
and after PEX treatment, including antibody titers.
4. Plasma exchange: clinical indications
4.1. Clinical indications: classification
PEX was prescribed with different volume, duration, frequency, number of performed pro-
cedures and different concomitant (immunosuppressive) therapy over the years. This is the 
reason for the relatively small number of randomized controlled trials (RCTs) concerning 
plasma exchange.
In order to evaluate the present data for the effectiveness of PEX in the treatment of different 
diseases, the American Society for Apheresis (ASFA) has classified the indications into four 
categories, according to the possible beneficial effect of PEX [16, 17]:
• ASFA category 1: Disorders for which apheresis is accepted as first-line therapy, either as a primary 
stand-alone treatment or in conjunction with other modes of treatment.
• ASFA category 2: Disorders for which apheresis is accepted as second-line therapy, either as a stand-
alone treatment or in conjunction with other modes of treatment.
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• ASFA category 3: Optimum role of apheresis therapy is not established. Decision-making should be 
individualized.
• ASFA category 4: Disorders in which published evidence demonstrates or suggests apheresis to be 
ineffective or harmful.
4.2. Clinical indications: renal diseases
4.2.1. Rapidly progressive glomerulonephritis
Rapidly progressive glomerulonephritis (RPGN) is a glomerular disease, associated with 
crescent formation in over 50% of the glomeruli, necrotic changes and rapid deterioration of 
kidney function. Kidney findings can be coupled with pulmonary hemorrhage, thus defining 
the Goodpasture’s syndrome. RPGN can be detected also in systemic lupus erythematosus 
(SLE), IgA nephropathy, post-infectious glomerular disease and systemic vasculitis [anti-neu-
trophil cytoplasmic antibodies (ANCA)-associated RPGN].
4.2.1.1. Anti-glomerular basement membrane disease
Anti-glomerular basement membrane (anti-GBM) disease or Goodpasture’s syndrome 
encompasses diseases with antibodies against the glomerular basement membrane. A term 
within this definition is Goodpasture’s disease, indicating disease associated with antibod-
ies against the α3 chain of collagen type 4, present in alveoli and glomeruli. Goodpasture’s 
syndrome can present with renal and pulmonary involvement—rapidly progressing renal 
failure, hemoptysis and pulmonary failure. PEX and immunosuppression (steroids, cyclo-
phosphamide) are the cornerstones of anti-GBM disease. Alveolar involvement is associated 
with high mortality; therefore, the presence of pulmonary hemorrhage is absolute indication 
for PEX (ASFA category 1) [16, 17]. Dialysis-independent patients with anti-GBM disease also 
fall in this category. In dialysis-dependent cases without alveolar hemorrhage, the effective-
ness of the method is reduced and is classified as ASFA category 3. Treatment should be 
performed daily/every other day for at least 14 days. Though ant-GBM antibody titers can be 
evaluated, the best way to assess effectiveness of the treatment is clinical outcomes [16].
4.2.1.2. ANCA-associated glomerular disease
The major representatives of this group are Wegener’s granulomatosis with polyangiitis, 
microscopic polyangiitis and Churg-Strauss syndrome. They are characterized with RPGN, 
systemic involvement, minimal or no immune deposits in the vascular wall and usually have 
elevated ANCA titers (ANCA/+/positive), though 10% of the cases are ANCA /−/negative. 
Treatment of ANCA/+/and ANCA/−/is similar and is based on immunosuppression and 
PEX. Immunosuppressive treatment includes high-dose steroids and cyclophosphamide. 
Rituximab can substitute cyclophosphamide too [18]. PEX is performed daily/every other day 
for 6–9 procedures. In cases of rapidly progressing kidney failure daily procedures are rec-
ommended. PEX is indicated in patients with pulmonary hemorrhage and on dialysis (ASFA 
category 1), whereas for dialysis-independent patients the effectiveness is significantly lower, 
therefore, categorized by ASFA as category 3 [16, 17].
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4.2.2. Infection-associated glomerular disease
Infection-associated glomerular disease consists of the following major subgroups of diseases:
• Bacterial infection-related diseases: Post-streptococcal glomerulonephritis (PSGN), infec-
tive endocarditis-related glomerulonephritis and shunt-associated glomerulonephritis
• Hepatitis C virus (HCV)-associated glomerular disease
• Hepatitis B virus (HBV)-related glomerular disease
• Human immunodeficiency virus (HIV)-related glomerular disease
• Protozoal infection-related glomerular disease
The cornerstone of infection-related glomerular disease is treatment of the underlying infec-
tion. However, in cases of histologically detected crescents, rapidly progressive GN, compli-
cating PSGN or schistosomiasis-related glomerulonephritis immunosuppressive treatment 
can be considered. In HCV – related glomerulonephritis, associated with presenting with 
mixed cryoglobulinemia (IgG/IgM), presenting with nephrotic proteinuria/acute flare of cryo-
globulinemia/rapid deterioration of kidney function, immunosuppressive treatment can be 
coupled with PEX [18]. PEX is effective in cryoglobulinemia and is categorized as ASFA cat-
egory 1 and is superior to IA. Generally, 3–8 procedures are required. Immunosuppression 
with rituximab was superior to other immunosuppressive agents [16].
4.2.3. Membranoproliferative glomerulonephritis
In cases of membranoproliferative glomerulonephritis (MPGN), an underlying disease (SLE, 
HCV or HBV infection, monoclonal gammopathies and rheumatologic disorders) should be 
ruled out. Idiopathic MPGN is treated with immunosuppressive agents. PEX is rarely indi-
cated, except for HCV-associated MPGN, complicated with cryoglobulinemia (Section 4.2.2). 
In all other cases of MPGN the use of PEX is under debate due to the small number of studies 
and the controversial results [19].
4.2.4. Minimal change disease and focal segmental glomerular sclerosis
Minimal change disease (MCD) and focal segmental glomerular sclerosis (FSGS) are disorders 
presenting with nephrotic syndrome. Several pathogenic mechanisms for increased protein loss in 
urine have been suggested, including the presence of permeability factors, increasing the permea-
bility of glomerular basement membrane (GBM) for proteins. Several molecules were considered 
for permeability factors (e.g., cardiotrophin-like cytokine 1), but currently no definite molecules 
proved to increase GBM permeability. Due to the similar pathogenesis and podocyte involve-
ment, MCD and FSGS are considered by most of the researchers as different steps in the progres-
sion of a single glomerular disease. Both MCD and FSGS have primary and secondary forms. The 
treatment of the secondary forms is based on the treatment of the underlying disease, whereas 
primary forms are treated with steroids or cyclophosphamide, mycophenolate mofetil and cal-
cineurin inhibitors [18]. Plasma exchange is not effective in FSGS and MCD in native kidneys. 
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LDL apheresis was found to have beneficial effects in steroid-resistant FSGS cases [20]. Long-
term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis is 
present. However, the data for this selective method in FSGS are insufficient and this modality 
is not widely available. PEX is indicated in recurrent FSGS after kidney transplantation (ASFA 
category 1), despite the inconsistent data for the efficacy in preserving graft function. At least nine 
procedures should be performed in recurrent FSGS, though the PEX can be prolonged for several 
months after improvement in proteinuria, by performing weekly or monthly procedures. In addi-
tion, pre-transplant PEX was found to reduce the incidence of recurrent FSGS [16, 17].
4.2.5. Membranous nephropathy
Membranous nephropathy (MN) is a glomerular disease, presenting with nephrotic syndrome. 
It has idiopathic and secondary forms (neoplasia, SLE, viral diseases). In primary MN auto-anti-
bodies against the M-type phospholipase A2 receptor were detected, possibly involved in the 
pathogenesis of the disease [21]. Treatment of MN is based on angiotensin-convertase enzyme 
(ACE) inhibitors, steroids, combined with cyclophosphamide or calcineurin inhibitors. Current 
guidelines do not suggest the use of PEX, though currently there are reports for successful treat-
ment of MN with PEX and rituximab/IVIG [9].
4.2.6. IgA nephropathy: Henoch-Schönlein purpura
IgA nephropathy (IgAN) is characterized by mesangial proliferation and deposits of immu-
noglobulin A in the mesangium. Henoch-Schönlein purpura (HSP) is a small vessel vasculitis, 
involving intestines, skin, joints and the kidney. Histologically the renal findings in HSP are 
similar to IgAN. A rare presentation of the disease is acute kidney injury due to crescentic 
glomerular involvement. Small studies indicate beneficial effects of PEX in crescentic IgAN 
[22]. However, guidelines do not support plasma exchange in IgAN or HSP (ASFA category 
3), even in the presence of crescents or severe extra-renal manifestations of HSP, due to the 
scarce data supporting plasmapheresis in these cases [16, 18].
4.2.7. Lupus nephropathy
PEX was found to have no significant effect on patients with lupus nephropathy (LN) in the 
randomized controlled trial [23] (AFSA category 4). A recent meta-analysis also established no 
significant effect of PEX in the treatment of proliferative LN [24]. In addition, IA was not supe-
rior to PEX in LN [16, 17]. PEX and IA are used in other presentations of SLE (the issue will be 
discussed in a different section).
4.2.8. Systemic amyloidosis
Plasma exchange is ineffective in systemic amyloidosis and falls into ASFA category 4, both 
for AA and for AL sub-forms [16]. However, β2 microglobulin adsorption was partially effec-
tive in β2 amyloidosis [17].
4.2.9. Kidney transplantation
PEX is used in three major directions—pre-transplantation treatment of sensitized/AB0 
incompatible patients, antibody removal in rejection and recurrent disease after KT.
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4.2.9.1. HLA-sensitized patients and AB0 incompatible KT
Desensitization protocols are used in candidates for KT in order to increase the donor pool in 
organ transplantation. Treatment of patients with HLA antibodies and positive cross-match 
reaction proved to be effective with excellent results for the 1-year graft survival. Different 
protocols exist, yet PEX or IA are the cornerstones of HLA desensitization protocols, accom-
panied by immunosuppressive treatment with IVIG or rituximab or both [25, 26]. Currently, 
bortezomib is being introduced in the immunosuppressive regimen. However, HLA desen-
sitization was not effective in deceased donors [16]. The treatment should aim for nega-
tive cross-match prior to KT. Despite the good short-term results, in the long term, there is 
increased incidence of rejection and poorer graft survival.
In AB0-incompatible KT, again protocols using PEX/IA, combined with IVIG/or/and ritux-
imab, are used (ASFA category 1) [16, 17]. The procedures are performed prior to and after 
KT. The treatment aim is reduction of anti-AB0 antibody titers from 1:4 to 1:32. Currently, 
short- and long-term graft survival is similar to AB0-compatible transplantation [27].
4.2.9.2. Antibody-mediated rejection
Antibody-mediated rejection (AbMR) is associated with histologically detected graft injury, 
positive C4d staining and the presence of circulating donor-specific antibodies. Both IA and 
PEX are used in the treatment of acute AbMR, in association with IVIG, 100–200 mg/kg, after 
each procedure [28]. Treatment should be accompanied with anti-T cell treatment with thy-
moglobulin. Rituximab can be added to the immunosuppressive protocol [29]. Usually 5–6 
procedures are performed.
Unfortunately, PEX in chronic AbMR is not as effective as in acute AbMR due to the irrevers-
ible changes in the graft [29].
4.2.9.3. Posttransplant recurrent glomerulonephritis
PEX/IA is the part of the first-line treatment in recurrent FSGS (Section 4.2.4). Recurrent 
anti-GBM disease is also an indication for aggressive plasma exchange. In recurrent ANCA-
associated glomerulonephritis, similar treatment to native kidneys should be initiated [30]. In 
MPGN, PEX can also be considered, though the data are scarce. Currently, there are no data 
to support the use of PEX in recurrent IgAN and membranous nephropathy. PEX also had 
controversial results in recurrent LN after KT [30].
4.3. Clinical indications: hematology
4.3.1. Thrombotic microangiopathies
Thrombotic microangiopathies (TMAs) are acute syndromes, characterized by hemolytic ane-
mia, thrombocytopenia and organ involvement due to microvascular thrombosis. It consists 
of two clinical aspects, having similar pathogenesis— hemolytic-uremic syndrome (HUS), 
presenting in children with predominant renal involvement, and thrombotic thrombocy-
topenic purpura (TTP), mainly in adults with severe neurologic presentation. The etiology 
encompasses the presence of autoantibodies, drugs, systemic diseases and pregnancy. The 
diagnosis should be made as early as possible, so that adequate treatment can be initiated.
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4.3.1.1. PEX treatment in HUS
Plasma exchange was found effective mainly in atypical HUS, especially in the presence 
of complement factor gene mutations (ASFA category II) and the presence of factor H 
autoantibody (ASFA category I). Treatment should be started as early as possible, with 
treatment volumes of 50 ml/kg, daily procedures for at least 5 days and with subsequent 
reduction of the PEX procedures per week. Substitution should be performed with FFP 
only. The decision to stop treatment should be taken based on the patient’s response and 
condition. In addition to PEX, treatment with rituximab and eculizumab can be added to 
the therapy [16].
4.3.1.2. PEX treatment in TTP
TTP is a potentially fatal disease and PEX has significantly improved survival in these patients. 
Therefore it is the first-line treatment in TTP. PEX is initiated at similar doses and daily pro-
cedures should be performed until platelet count rises above 150 × 109/l for three consecutive 
days. Supplementation should be made with FFP/cryoprecipitate poor plasma. Afterwards, 
procedures can be performed less frequently, though no data exist. Additionally, steroids and 
rituximab can be used in the treatment.
4.3.1.3. PEX in drug-related TMA
TMA is associated with the use of several drug classes—calcineurin inhibitors, medications 
reducing platelet aggregation (ticlopidine, clopidogrel) and so on. Of these, PEX proved to 
be an effective option in ticlopidine-associated TMA. In all other medications, PEX was not 
associated with clear improvement in patient outcomes [16, 17].
4.3.2. Multiple myeloma
Multiple myeloma has a wide spectrum of renal involvement, spanning from myeloma cast 
nephropathy, AL amyloidosis to cryoglobulinemia and membranoproliferative glomerulone-
phritis. Chemotherapy is the crucial part of the treatment. AL amyloidosis is not significantly 
influenced by PEX [16]. The effect of PEX in myeloma cast nephropathy was also evaluated 
in the past. However, the results so far are conflicting. Therefore, the use of PEX in everyday 
practice is not recommended [31].
4.3.3. Waldenström macroglobulinemia
Increased serum levels of plasma proteins increase serum viscosity, leading to small vessel 
damage, especially small veins. Clinically, hyperviscosity presents with retinopathy and neu-
rological symptoms (headache, somnolence, coma and seizures). Hyperviscosity syndrome is 
usually detected in Waldenström macroglobulinemia and multiple myeloma. Generally, the 
treatment of the diseases is chemotherapy. PEX is applied in cases of symptoms  associated 
with hyperviscosity. Generally, when substitution volume is 50 ml/kg, human albumin is 
used. Symptoms are relieved after 1–3 procedures; after that PEX can be discontinued or pro-
phylactic procedures monthly can be performed [16, 17].
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4.3.4. Autoimmune hemolytic anemia
Autoimmune hemolytic anemia (AIHA) is a disorder in which autoantibodies cause either 
intravascular or extravascular destruction of red blood cells (RBCs). AIHA is categorized in two 
major groups—warm AIHA (antibodies reacting at body temperature) and cold agglutinin dis-
ease (CAD, hemolysis occurring at temperatures between 0 and 5°C). The first-line treatment for 
warm AIHA is prednisolone; rituximab is used as the second-line agent. In CAD the primary goal 
is avoidance of exposure to the cold; in severe cases rituximab is the drug of choice. The results 
for PEX treatment in warm AIHA are conflicting; therefore, its use is limited to severe cases of 
fulminant AIHA. In CAD, PEX has shown no effect in terms of improvement of long-term out-
comes. Due to the risk of agglutination at room temperature for CAD, the procedure should be 
performed at higher temperatures for both extracorporeal circuit and room temperature.
4.3.5. Aplastic anemia
Aplastic anemia (AA) and pure red cell aplasia (PRCA) are rare hematopoietic stem cell dis-
orders. In AA there is pluripotent progenitor cell involvement, causing pancytopenia and 
hypocellular bone marrow. In PRCA only erythroid progenitors are affected, leading to nor-
mochromic, normocytic anemia, reticulocytopenia, severe reduction in marrow erythroid pre-
cursors and normal myelo- and lymphopoiesis, as well as platelet production. The diseases 
can be idiopathic, as well as secondary, due to infection, neoplasia, chemicals and drugs. As 
the pathogenesis of the conditions is mostly immunological (the presence of autoantibodies 
was established), immunosuppressive agents are usually used as first-line treatment. PEX can 
also be considered in immunosuppression-resistant cases. PEX is performed until hematopoi-
esis/erythropoiesis recovers [16].
4.3.6. Hematopoietic stem cell transplantation
PEX is used in the case of AB0-incompatible hematopoietic stem cell transplantation (HSCT) 
and in HLA desensitization protocols. There are two types of AB0-incompatible HSCT—major 
and minor ones. In major AB0-incompatible HSCT, natural isoagglutinins in the recipient 
against the donor’s A and/or B blood group antigens are present. They cause acute hemolysis 
of the RBCs present in infused hematopoietic progenitor cell (HPC) products. In minor AB0-
incompatible HSCT, isoagglutinins cause hemolysis only if the antibodies are in high titers 
(above 1:128). In major AB0-incompatible HSCT, PEX and IA are used to reduce the titers of 
natural isoagglutinins. Procedures are performed daily, substitution volume is usually 50 ml/
kg, and substitution fluid includes albumin and donor- and recipient-compatible FFP. The 
reduction of isoagglutinin titers below 1:16 is aimed prior to HSCT.
In HLA-sensitized patients there is reduced graft survival after HSCT. Reports indicate that 
successful procedure after desensitization is performed. PEX is used to remove donor-specific 
antibodies and is coupled with immunosuppression (IVIG, rituximab, bortezomib). However, 
the data considering the use of PEX in desensitization protocols are scarce. PEX usually is 
used every other day, aiming at negative cross-match test prior transplantation.
PEX is not recommended in graft versus host disease (GVHD). In these cases extracorporeal 
photopheresis (ECP) has a beneficial effect [17].
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4.4. Clinical indications: neurology
4.4.1. Neurological diseases from ASFA category 1
In the following neurological conditions, PEX has beneficial effects and is considered as first-
line treatment: Guillain-Barre Syndrome, chronic inflammatory demyelinating polyradiculo-
neuropathy, myasthenia gravis, Sydenham’s chorea, N-methyl D-aspartate receptor antibody 
encephalitis and progressive multifocal leukoencephalopathy associated with natalizumab 
[16, 17]. The diseases are autoantibody mediated; therefore, PEX has a crucial role in remov-
ing the main pathogenic factor. In addition, immunosuppression is performed (steroids, cal-
cineurin inhibitors, rituximab and IVIG). Generally, plasma exchange is performed 5–6 times 
for 10–14 days, or 2–3 procedures per week, where substitution volume is 50 ml/kg and albu-
min solutions are preferred. The procedure is performed until symptoms resolve, though 
maintenance PEX can also be considered.
4.4.2. Neurological diseases from ASFA category 2
The following diseases belong to this category: acute disseminated encephalomyelitis, acute 
neuromyelitis optica, Lambert-Eaton myasthenic syndrome, acute demyelinating multiple 
sclerosis and voltage gated potassium channel antibodies. The conditions are also autoim-
mune mediated, but the first-line treatments are immunosuppressive agents (steroids, IVIG 
and rituximab). PEX comes as a second-line treatment. Technically, the procedure is per-
formed as the recommendations in Chapter 4.4.1.
4.4.3. Neurological diseases from ASFA category 3
Several neurological conditions fall into this category: chronic focal encephalitis, post-IVIG 
Guillain-Barre Syndrome, chronic progressive multiple sclerosis and paraneoplastic neuro-
logical syndromes. In these diseases, the most important part of the treatment is immunosup-
pression/anticancer treatment. There are conflicting results for the use of PEX/IA, in most of 
the cases aiming at slowing down the progression of the disease. Usually 3–6 PEX procedures 
every other day are performed. If IA is considered then 2–3 procedures/week must be con-
ducted. Maintenance protocols have also been suggested [16].
4.4.4. Neurological diseases from ASFA category 4
In amyotrophic lateral sclerosis, dermatomyositis/polymyositis and inclusion body myositis, 
the use of PEX was not superior to conservative treatment alone; therefore, its use in clinical 
practice is currently not recommended.
4.5. Clinical indications: rheumatology
4.5.1. Systemic lupus erythematosus
SLE is an autoimmune disease, with involvement of several organs. It is an incurable, chronic, 
remitting and relapsing disease. Immunosuppressive agents are first-line treatments for SLE 
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(steroids, cyclophosphamide, azathioprine, biological agents, etc.). PEX was regarded as a 
treatment option due to the presence of pathogenic autoantibodies. However, the trials so far 
failed to establish improvement of the prognosis in mild SLE. In severe SLE (presence of TTP, 
cerebritis, alveolar hemorrhage and cryoglobulinemia), PEX coupled with immunosuppres-
sion demonstrated improvement in clinical outcomes. Therefore, severe SLE is classified as 
ASFA category 2. Lupus nephritis is not significantly influenced by PEX (ASFA category 4), 
except for the cases with LN and TTP [18]. Plasma exchange is performed daily/every other 
day; usually 3–6 procedures are sufficient in lupus cerebritis and alveolar hemorrhage.
4.5.2. Antiphospholipid syndrome
Antiphospholipid syndrome (APS) is a hypercoagulable state characterized by episodes of 
vascular thrombosis and the presence of antiphospholipid antibodies. It can be associated 
with SLE, though non-SLE APS is also present. Catastrophic APS is a rare disease, character-
ized by APS and multi-organ failure. The mainstay of the treatment is treatment of etiological 
factors and anticoagulation. The role of PEX is not clearly defined; it is suggested that it is 
involved in antibody and cytokine removal. In order to optimize the effect, substitution fluids 
should contain FFP as a source for proteins C and S; therefore, substitution with FFP and albu-
min is performed. The procedures are performed daily, there is no clear guideline in terms of 
duration and clinical response remains the most important indicator.
4.5.3. Scleroderma
Scleroderma is a progressive disease of unknown origin, with skin and visceral organ involve-
ment. Currently, the cornerstone of the treatment is D-penicillamine. Immunosuppressive 
agents are used too. So far two therapeutic options have been evaluated—PEX and extracor-
poreal photopheresis (ECP). Despite several reports indicating beneficial effects of the proce-
dures, the data are conflicting; therefore, the disease is categorized as ASFA category 3.
4.5.4. Polyarteritis nodosa
Polyarteritis nodosa (PAN) is a vasculitis, involving medium-sized arteries, presenting with 
multi-organ involvement. The disease is idiopathic, or secondary, associated with infection 
[hepatitis B (HBV)]. In HBV-associated PAN the current treatment strategy includes steroids 
and antiviral agents. PEX is used as second ß line agent, and its beneficial effect is explained 
with removal of immune complexes. Idiopathic PAN is treated with steroids and cyclophos-
phamide. PEX in these cases is not recommended [17]. The usual substitution volume and 
albumin solutions are used. In HBV-associated PAN, 2–3 procedures per week are performed.
4.6. Clinical indications: endocrinology and metabolic disease
4.6.1. Thyroid storm
Thyroid storm is an extreme manifestation of thyrotoxicosis. Conservative treatment is 
the first-line therapy and encompasses medications which stop the synthesis, release and 
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peripheral effects of the thyroid hormones. Once these first- and second-line choices fail to 
have effects, third-line treatment, such as PEX, is considered. PEX reduces serum levels of the 
hormones, as well as provides thyroglobulin, thus binding free thyroid hormones. Therefore, 
FFP and albumin should be considered for PEX in the thyroid storm. The procedures are per-
formed daily until clinical improvement is established.
4.6.2. Diabetes mellitus type 1
Autoimmune destruction of the β cells of the pancreas is a key factor for the development of 
diabetes mellitus (DM) type 1. Therefore, PEX was evaluated as a possible treatment of DM 
type 1. Though several reports demonstrated improvement in clinical outcomes, the overall 
results are conflicting and PEX is not recommended in the treatment of the disease.
4.6.3. Familial hypercholesterolemia
Familial hypercholesterolemia (FH) is an autosomal dominant disorder, associated with muta-
tions of hepatocyte apolipoprotein-B (apo-B) receptors, resulting in decreased hepatic LDL 
removal. It is characterized with elevated total cholesterol and LDL levels, early atherosclero-
sis and death from cardiovascular events (especially in homozygotes). Conservative treatment 
reduces LDL from 10 to 49%. In progressive diseases, interventional techniques including PEX 
and LDL apheresis are considered. Generally, the indications for LDL apheresis are failure of 
the conservative treatment (LDL reduction ˂50%) and progressive coronary artery disease. 
The results for LDL apheresis in homozygotes are excellent, and FH in these cases is classified 
in ASFA category 1. Apart from PEX, there are several selective LDL removal techniques:
• immunoadsorption
• electrostatic removal of apo-B lipoproteins by dextran sulfate columns
• heparin extracorporeal LDL precipitation (HELP) by precipitation of apo-B in the presence 
of heparin and low pH
• hemoperfusion-based direct adsorption of lipoprotein
• membrane differential filtration, filtering LDL from plasma.
Volumes in LDL apheresis vary; for PEX, standard volume of 50 ml/kg is suggested. The 
procedure is performed once per 1–2 weeks. The patients may require arteriovenous fistula 
for the treatment.
4.6.4. Fulminant Wilson disease
Wilson disease is an autosomal recessive genetic disorder, characterized by impaired biliary 
copper excretion and copper accumulation in the liver, brain, cornea and kidneys. Fulminant 
forms are associated with severe liver failure and multi-organ failure. The ultimate treatment 
is liver transplantation (LT), but PEX can be used as bridging therapy, due to the reduced 
donor pool. PEX is beneficial due to rapidly reducing copper levels, as well as providing 
coagulation factors via plasma infusion. The reports however are scarce. Due to the wider 
availability, PEX is usually preferred to molecular adsorbents recirculating system (MARS). 
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Substitution fluid should consist of FFP/FFP and albumin. The frequency is daily/every other 
day, until clinical and laboratory improvement is detected.
4.7. Clinical indications: cardiology and pulmonology
4.7.1. Lung allograft rejection
Different therapeutic apheresis modalities were evaluated after lung transplantation in the 
following conditions—bronchiolitis obliterans syndrome (BOS) and antibody-mediated rejec-
tion (AbMR). BOS is an increasing airflow obstruction, due to chronic rejection. AbMR after 
lung transplantation is an important cause for graft loss and diagnostic criteria are currently 
assessed. The first-line treatment for the two conditions is immunosuppression. In BOS ECP 
can be considered as second-line treatment. ECP probably decreases levels of effector T cells 
while at the same time expanding regulatory T cells, thus influencing the immune response. 
ECP had beneficial effects in several studies, in patients unresponsive to immunosuppres-
sion. In addition, it did not increase the risk for infection complications. Unfortunately, the 
data so far are scarce. Different approaches have been suggested, for example, 24 procedures 
for 6 months [16]. PEX is recommended as treatment of choice in resistant AbMR, though the 
results are inconclusive.
4.7.2. Cardiac allograft transplantation
There are two apheresis modalities used in cardiac transplantation. PEX is used in sensitized 
patients and in the treatment of antibody-mediated acute rejection, together with immuno-
suppressive agents [32]. PEX is crucial in desensitization protocols, whereas in AbMR, the 
results are still controversial. ECP is an option in cellular rejection and rejection prophylaxis 
[17]. The procedures are performed until improvement in laboratory, clinical and histological 
findings is achieved.
4.7.3. Idiopathic dilated cardiomyopathy
Idiopathic dilated cardiomyopathy (IDC) is characterized by cardiac enlargement and 
deteriorating heart function of unknown origin. External factors were detected, as well as 
autoantibodies against the myocardium. Current treatment encompasses conservative 
treatment (ACE inhibitors, diuretics, etc.). However, PEX and IA also were evaluated. IA 
showed improvement in clinical outcomes in adult patients. Small studies also demonstrated 
beneficial effects from PEX in ICD in adults and children [17, 33]. IA usually is performed 
daily/every other day for a total number of five procedures. Similar treatment protocol for 
PEX is suggested.
4.8. Clinical indications: dermatology
4.8.1. Pemphigus vulgaris
Pemphigus vulgaris (PV) is an autoimmune, potentially fatal disease, with mucocutaneous 
involvement. The cornerstone of the treatment is immunosuppressive agents and steroids. 
PEX and IA have been tested, aiming at reduction of the antibody titers. Clinical results, 
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however, are conflicting. Currently PEX/IA can be considered in severe cases of PV (ASFA 
category 3). PEX is performed daily/every other day, in cases of IA it is done three times per 
week, and then gradually tapered. Procedures are performed until clinical improvement is 
noted and a significant drop in autoantibody titer is achieved.
4.8.2. Toxic epidermal necrolysis
Toxic epidermal necrolysis (TEN) is a life-threatening skin disorder, characterized by wide-
spread erythema, necrosis, epidermal detachment, erosion of mucous membranes and sys-
temic clinical symptoms (fever, sepsis, multi-organ failure). The etiology of the condition 
encompasses medications, infections, solid organ transplantation and bone marrow transplan-
tation. The major aspects of current treatment are etiologic treatment, supportive care, fluid 
resuscitation and treatment of infectious complications. Due to the marked heterogeneity of 
the reports considering PEX in TEN, currently it is considered as part of the treatment only in 
refractory cases. The procedure is performed daily/every other day, and up to five procedures 
are usually performed.
4.8.3. Psoriasis vulgaris
Psoriasis is a skin disease that is accompanied by systemic inflammation and is characterized 
by epidermal hyperproliferation and dermal inflammation. Different treatment modalities 
are used—from topical medications, ultraviolet light to systemic agents (immunosuppres-
sive agents and biological formulations). PEX is not indicated in psoriasis (ASFA category 4). 
However, ECP was found to have beneficial effects in disseminated forms.
4.9. Clinical indications: gastroenterology
4.9.1. Acute liver failure (ALF)
Acute liver failure (ALF) can develop in the setting of healthy liver (fulminant hepatic 
failure) or on top of chronic liver disease. The condition is associated with high mortal-
ity; prognosis depends on etiology. Generally, conservative treatment is the cornerstone 
of treatment. In patients with ALF and poorer prognosis for improvement, liver support 
systems are used for bridging therapy to liver transplantation. Liver support systems 
generally are of two types—cell-based (currently experimental) and non-cell-based sup-
port systems— and include PEX, albumin dialysis, MARS and selective plasma exchange. 
Apheresis probably improves outcomes in ALF due to removal of toxins and inflammatory 
cytokines. Use of PEX had better clinical outcomes compared to patients not treated with 
PEX. PEX combined with MARS improved bilirubin clearance versus PEX only, though 
clinical outcomes were similar in both groups. A recent study demonstrated that high-
volume PEX (treated volume reaching 15% of body weight) effectively improves survival, 
compared to standard medical care. Unfortunately, the technique is not available world-
wide. The procedures (PEX or high-volume PEX) should be performed daily, until clinical 
and laboratory improvement is noted or liver transplantation is performed. Substitution 
fluid should include FFP and albumin.
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4.9.2. Liver transplantation
PEX is increasingly being used in AB0-incompatible liver transplantation (LT). The most benefi-
cial effect was detected in living donation; the procedure is coupled with immunosuppression 
(IVIG, rituximab). In AB0-incompatible LT in living donation, PEX is a first-line treatment prior 
to the operation. In deceased donation, PEX can also be applied in AB0 incompatibility. The 
reports are limited in number. In addition, the effectivity of PEX is reduced in the setting of 
cadaver transplantation and urgent LT. In these cases crossover LT can be considered. PEX had 
a beneficial effect in antibody-mediated rejection after LT. However, the reports are predomi-
nantly retrospective ones, and further evaluation of PEX effectivity in humoral rejection after LT 
is needed. Procedures are performed daily until negative cross-match test is achieved. No titers 
for natural agglutinins were suggested. In humoral rejection, clinical and laboratory parameters 
should be evaluated.
4.9.3. Inflammatory bowel disease
The cornerstone of inflammatory bowel disease (IBD) treatment is conservative treatment 
(immunosuppressive agents and biological agents). PEX is not indicated in IBD; however, 
cytapheresis techniques were evaluated. The results are still insufficient to incorporate these 
invasive methods in everyday practice.
4.10. Clinical indications: sepsis and poisoning
4.10.1. Sepsis
Sepsis, especially associated with multi-organ failure, is a condition with mortality peaking 
up to 70%. The mainstay of treatment is antibiotics, fluid resuscitation and so on. The possible 
beneficial effect of PEX is removal of inflammatory molecules and replenishing anticoagulant 
proteins. Selective techniques have been evaluated too. Despite the promising results from 
retrospective studies, prospective trials showed conflicting results of PEX use in improving 
clinical outcomes. The substitution volume is 50 ml/kg, and substitution fluid should be FFP 
[17]. The procedures should be performed in intensive care unit and are performed daily.
4.10.2. Exogenous intoxications
This category encompasses three conditions—drug overdose/poisoning, envenomation and 
mushroom poisoning. The mechanism of action of each agent is different; therefore, different treat-
ment options are used. The basic treatment options currently are stabilization of airways, breath-
ing, circulation, gastric lavage, oral charcoal administration and forced diuresis. More aggressive 
approaches include hemodialysis and hemoperfusion. PEX was evaluated in mushroom poisoning 
and demonstrated improvement in survival, especially if early initiation is performed. The reports 
concerning PEX in envenomation are anecdotal. Data for PEX in drug poisoning are insufficient 
too. Generally, PEX can be used in drug poisoning with molecules having high-protein binding. 
The usual substitution volume is recommended, substitution fluid is albumin, but FFP can also be 
considered, especially if coagulopathy is present. PEX is performed daily until clinical symptoms 
resolve.
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4.11. Clinical indications: oncology
4.11.1. Hematological malignancies
The use of PEX in multiple myeloma and Waldenström disease has already been discussed. 
Generally, PEX is not used in other hematological malignancies. However, other techniques 
(e.g., ECP) are recommended in cutaneous T-cell lymphoma [17]. In addition, leucapheresis and 
plateletpheresis can be performed in life-threatening leukemia/myeloproliferative disorders [2].
4.11.2. Solid tumors
Several reports indicated improvement in clinical outcomes in solid tumors and metastatic 
cancer [2]. A possible explanation is that via PEX, inhibitory molecules are removed from 
plasma, thus improving immune response. Due to the heterogeneity of the studies and the 
conflicting results, no clear indications for PEX in these cases are defined. Further studies in 
this field are needed.
5. Conclusion
There are three major obstacles for the adequate evaluation of PEX effectiveness—the small 
number of patients enrolled, small number of randomized controlled trials and high cost 
of the procedure. However, with the advance of the technique and adequate collection of 
data on PEX use, these obstacles can gradually be overcome in the future. A more interesting 
perspective is the development of more selective techniques, as well as the use of magnetic 
separation and cell filtration. Thus, we can expect wider use of apheresis in medical practice 
in the future.
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